Reviews in Endocrine and Metabolic Disorders

, Volume 14, Issue 3, pp 273–286 | Cite as

Metabolic syndrome and associated chronic kidney diseases: Nutritional interventions

  • P. Anil KumarEmail author
  • P. Swathi Chitra
  • G. Bhanuprakash Reddy


Lifestyle changes such as dietary habits, sedentary life and consumption of energy-dense foods that have occurred over the years has led to an epidemic of abdominal obesity, which in turn resulted in dramatic increase in the prevalence of metabolic syndrome (MetS). Different expert panels have provided various definitions for MetS to enable a clinical diagnosis and treatment of patients at risk of associated complications. Obesity and obesity mediated MetS has been paralleled by escalation in the incidence of chronic kidney disease (CKD). A better understanding of the pathophysiology of MetS and identification of individuals with MetS early in the life course could be important for initiating interventions such as lifestyle modification and dietary restrictions that form the basis for prevention and treatment of MetS and related co-morbidities including CKD. This review is intended to provide a comprehensive summary of the evolution of definition of MetS and association of MetS with CKD. In particular, mechanism of obesity and diabetes mediated CKD and emerging dietary therapies for MetS associated CKD will be discussed.


Metabolic syndrome Obesity Hyperglycemia Renal complications Chronic kidney disease End-stage kidney disease 



Grants from DST-INSPIRE (to PAK); DST and DBT (to GBR), Government of India are acknowledged. Owing to space limitations a number of interesting publications could not be mentioned herein.

Conflict of interest

The authors have no conflict of interests in the data presented in this review.


  1. 1.
    Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet. 2005;365:1415–28.PubMedCrossRefGoogle Scholar
  2. 2.
    Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care. 2011;34:216–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Kylin E. Studien ueber das Hypertonie-Hyperglyka “mie-Hyperurika” miesyndrom. Zbl Innere Med. 1923;44:105–27.Google Scholar
  4. 4.
    Vague J. La differenciation sexuelle, facteur determinant des formes de l’obesité. Presse Med. 1947;53:339–40.Google Scholar
  5. 5.
    Avogaro P, Crepaldi G. Essential hyperlipidemia, obesity and diabetes. Diabetologia. 1965;1:137.Google Scholar
  6. 6.
    Hanefeld M, Leonhardt W. The metabolic syndrome [Das metabolische syndrom]. Dtsch Gesundheitsw. 1981;36:545–51.Google Scholar
  7. 7.
    Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes. 1998;37:1595–607.CrossRefGoogle Scholar
  8. 8.
    Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149:1514–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Haffner SM, Valdez RA, Hazuda HP, et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41:715–22.PubMedCrossRefGoogle Scholar
  10. 10.
    Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and its complications. Part1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.Google Scholar
  11. 11.
    Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442–3.PubMedCrossRefGoogle Scholar
  12. 12.
    Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic waist: a marker of the atherogenic metabolic triad (hyperinsulinemia;hyperapolipoprteinB;small dense LDL) in men? Circulation. 2000;102:179–84.PubMedCrossRefGoogle Scholar
  13. 13.
    Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.Google Scholar
  14. 14.
    Einhorn D, Reaven GM, Cobin RH, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003;9:237–52.PubMedGoogle Scholar
  15. 15.
    Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2002;25:829–34.PubMedCrossRefGoogle Scholar
  16. 16.
    Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.PubMedCrossRefGoogle Scholar
  17. 17.
    Grundy SM, Cleeman JI, Daniels SR, American Heart Association; National Heart, Lung, and Blood Institute, et al. Circulation. 2005;112:2735–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Cameron AJ, Magliano DJ, Zimmet PZ, et al. The metabolic syndrome in Australia: prevalence using four definitions. Diabetes Res Clin Pract. 2007;77:471–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Doupis J, Dimosthenopoulos C, Diamanti K, et al. Metabolic syndrome and Mediterranean dietary pattern in a sample of young, male, Greek navy recruits. Nutr Metab Cardiovasc Dis. 2009;19:e7–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005;28:1769–78.PubMedCrossRefGoogle Scholar
  22. 22.
    Nitta K. Possible link between metabolic syndrome and chronic kidney disease in the development of cardiovascular disease. Cardiol Res Pract. 2011;2011:963517.Google Scholar
  23. 23.
    Resnick HE, Jones K, Ruotolo G, et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic American Indians: the Strong Heart Study. Diabetes Care. 2003;26:861–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143:722–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Lin WY, Liu CS, Li TC, et al. In addition to insulin resistance and obesity, hyperuricemia is strongly associated with metabolic syndrome using different definitions in Chinese populations: a population-based study. Ann Rheum Dis. 2008;67:432–3.PubMedCrossRefGoogle Scholar
  26. 26.
    Singh AK, Kari JA. Metabolic syndrome and chronic kidney disease. Curr Opin Nephrol Hypertens. 2013;22:198–203.PubMedCrossRefGoogle Scholar
  27. 27.
    Kramer H, Luke A, Bidani A, et al. Obesity and prevalent and incident CKD: the hypertension detection and follow-up program. Am J Kidney Dis. 2005;46:587–94.PubMedCrossRefGoogle Scholar
  28. 28.
    Othman M, Kawar B, El Nahas AM. Influence of obesity on progression of nondiabetic chronic kidney disease: a retrospective cohort study. Nephron Clin Pract. 2009;113:c16–23.PubMedCrossRefGoogle Scholar
  29. 29.
    Gelber RP, Kurth T, Kausz AT, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis. 2005;46:871–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Chadban SJ, Briganti EM, et al. Prevalence of kidney damage in Australian adults: the AusDiab kidney study. J Am Soc Nephrol. 2003;14(7 Suppl 2):S131–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Stevens PE, O'Donoghue DJ, et al. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007;72(1):92–9.PubMedCrossRefGoogle Scholar
  32. 32.
    K/DOQI. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1–S266.Google Scholar
  33. 33.
    van der Velde M, Bakker SJ, de Jong PE, Gansevoort RT. Influence of age and measure of eGFR on the association between renal function and cardiovascular events. Clin J Am Soc Nephrol. 2010;5:2053–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005;16:2134–40.PubMedCrossRefGoogle Scholar
  35. 35.
    Weisinger JR, Kempson RL, Eldridge FL, Swenson RS. The nephritic syndrome: a complication of massive obesity. Ann Intern Med. 1974;81:440–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Klausen KP, Parving HH, Scharling H, Jensen JS. Microalbuminuria and obesity: impact on cardiovascular disease and mortality. Clin Endocrinol (Oxf). 2009;71:40–5.CrossRefGoogle Scholar
  37. 37.
    Pinto-Sietsma SJ, Navis G, Janssen WM, et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis. 2003;41:733–41.PubMedCrossRefGoogle Scholar
  38. 38.
    Praga M, Hernandez E, Herrero JC, et al. Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int. 2000;58:2111–8.PubMedCrossRefGoogle Scholar
  39. 39.
    Praga M. Obesity—a neglected culprit in renal disease. Nephrol Dial Transplant. 2002;17:1157–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59:1498–509.PubMedCrossRefGoogle Scholar
  41. 41.
    Deji N, Kume S, Araki S, et al. Structural and functional changes in the kidneys of high-fat diet-induced obese mice. Am J Physiol Ren Physiol. 2009;296:F118–26.CrossRefGoogle Scholar
  42. 42.
    Chen J, Muntner P, Hamm LL, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140:167–74.PubMedCrossRefGoogle Scholar
  43. 43.
    Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003;16:952–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Thomas G, Sehgal AR, Kashyap SR, et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6:2364–73.PubMedCrossRefGoogle Scholar
  45. 45.
    Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:550–62.PubMedCrossRefGoogle Scholar
  46. 46.
    Espinoza R, Gracida C, Cancino J, et al. Effect of obese living donors on the outcome and metabolic features in recipients of kidney transplantation. Transplant Proc. 2006;38:888–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Hsu CY, McCulloch CE, Iribarren C, Darbinian J. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144:21–8.PubMedCrossRefGoogle Scholar
  48. 48.
    Ejerblad E, Fored M, Lindblad P, Fryzek J, McLaughlin JK, Nyren O. Obesity and risk of chronic renal failure. J Am Soc Nephrol. 2006;17:1695–702.PubMedCrossRefGoogle Scholar
  49. 49.
    Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12:1211–7.PubMedGoogle Scholar
  50. 50.
    Abitbol CL, Rodriguez MM. Obesity-related nephropathy in children. Pediatr Health. 2009;3:141–53.CrossRefGoogle Scholar
  51. 51.
    Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol. 2006;17:2985–91.PubMedCrossRefGoogle Scholar
  52. 52.
    Goossens GH, Blaak EE, van Baak MA. Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev. 2003;4:43–55.PubMedCrossRefGoogle Scholar
  53. 53.
    Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol. 2004;15:2792–800.PubMedCrossRefGoogle Scholar
  54. 54.
    Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448–54.PubMedCrossRefGoogle Scholar
  55. 55.
    Ramkumar N, Cheung AK, Pappas LM, Roberts WL, Beddhu S. Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. J Ren Nutr. 2004;14:201–7.PubMedGoogle Scholar
  56. 56.
    Wu Y, Liu Z, Xiang Z, Zeng C, Chen Z, Ma X, et al. Obesity-related glomerulopathy: insights from gene expression profiles of the glomeruli derived from renal biopsy samples. Endocrinology. 2006;147:44–50.PubMedCrossRefGoogle Scholar
  57. 57.
    Camici M, Galetta F, Abraham N, Carpi A. Obesity-related glomerulopathy and podocyte injury: a mini review. Front Biosci (Elite Ed). 2012;4:1058–70.Google Scholar
  58. 58.
    Kirschenbaum MA, Pai R, Roh DD, Kamanna VS. Role of atherogenic lipoproteins in cytokine-mediated renovascular injury. Miner Electrolyte Metab. 1996;22:47–50.PubMedGoogle Scholar
  59. 59.
    Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548–56.PubMedCrossRefGoogle Scholar
  60. 60.
    Yano Y, Hoshide S, Ishikawa J, et al. Differential impacts of adiponectin on low-grade albuminuria between obese and nonobese persons without diabetes. J Clin Hypertens (Greenwich). 2007;9:775–82.CrossRefGoogle Scholar
  61. 61.
    Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M, et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17:2599–606.PubMedCrossRefGoogle Scholar
  62. 62.
    Sharma K, Ramachandrarao S, Qiu G, et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008;118:1645–56.PubMedGoogle Scholar
  63. 63.
    Ma K, Cabrero A, Saha PK, et al. Increased beta -oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin. J Biol Chem. 2002;277:34658–61.PubMedCrossRefGoogle Scholar
  64. 64.
    Ohashi K, Iwatani H, Kihara S, et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin knockout mice. Arterioscler Thromb Vasc Biol. 2007;27:1910–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int. 2009;76:145–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Wolf G, Hamann A, Han DC, et al. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: potential role in glomerulosclerosis. Kidney Int. 1999;56:860–72.PubMedCrossRefGoogle Scholar
  67. 67.
    Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol. 2006;151:175–83.PubMedCrossRefGoogle Scholar
  68. 68.
    Menzaghi C, Salvemini L, Fini G, et al. Serum resistin and kidney function: a family-based study in non-diabetic, untreated individuals. PLoS One. 2012;7:e38414.PubMedCrossRefGoogle Scholar
  69. 69.
    Nehus EJ. Correlates of resistin in children with chronic kidney disease: the CKiD Cohort. Electronic Thesis. University of Cincinnati, 2011.
  70. 70.
    D'Elia JA, Roshan B, Maski M, Weinrauch LA. Manifestation of renal disease in obesity: pathophysiology of obesity-related dysfunction of the kidney. Int J Nephrol Renov Dis. 2009;2:39–49.Google Scholar
  71. 71.
    Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol. 2004;15:2775–91.PubMedCrossRefGoogle Scholar
  72. 72.
    Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol. 2004;24:46–53.PubMedCrossRefGoogle Scholar
  73. 73.
    Nishida Y, Yorioka N, Oda H, Yamakido M. Effect of lipoproteins on cultured human mesangial cells. Am J Kidney Dis. 1997;29:919–30.PubMedCrossRefGoogle Scholar
  74. 74.
    Anil Kumar P, Bhanuprakash Reddy G. Focus on molecules: aldose reductase. Exp Eye Res. 2007;85:739–40.PubMedCrossRefGoogle Scholar
  75. 75.
    Uribarri J, Tuttle K. Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol. 2006;1:1293–9.PubMedCrossRefGoogle Scholar
  76. 76.
    Schwedler SB, Metzger T, Schinzel R, et al. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int. 2002;62:301–10.PubMedCrossRefGoogle Scholar
  77. 77.
    Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerularsclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A. 1994;91:11704–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162:1123–37.PubMedCrossRefGoogle Scholar
  79. 79.
    Isaka Y, Fujiwara Y, Ueda N, et al. Glomerulosclerosis induced in vivo transfection of transforming growth factor beta or platelet derived growth factor gene into rat kidney. J Clin Invest. 1992;92:2597–601.CrossRefGoogle Scholar
  80. 80.
    Langham RG, Kelly DJ, Gow RM, et al. Transforming growth factor-β in human diabetic nephropathy, effects of ACE inhibition. Diabetes Care. 2006;29:2670–4.PubMedCrossRefGoogle Scholar
  81. 81.
    Sahib MN, Abdulameer SA, Aziz NA, Hassan Y. Pathogenesis of diabetic kidney disease: review of cellular aspects of renal lesions. Afr J Pharm Pharmacol. 2009;3:507–14.Google Scholar
  82. 82.
    Kumar PA, Brosius 3rd FC, Menon RK. The glomerular podocyte as a target of growth hormone action: implications for the pathogenesis of diabetic nephropathy. Curr Diabetes Rev. 2011;7:50–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Kumar PA, Kotlyarevska K, Dejkhmaron P, et al. Growth hormone (GH)-dependent expression of a natural antisense transcript induces zinc finger E-box-binding homeobox 2 (ZEB2) in the glomerular podocyte: a novel action of gh with implications for the pathogenesis of diabetic nephropathy. J Biol Chem. 2010;285:31148–56.PubMedCrossRefGoogle Scholar
  84. 84.
    Gnudi L, Viberti G, Raij L, et al. GLUT-1 overexpression: link between hemodynamic and metabolic factors in glomerular injury? Hypertension. 2003;42:19–24.PubMedCrossRefGoogle Scholar
  85. 85.
    Riccardi G, Rivellese AA. Dietary treatment of the metabolic syndrome–the optimal diet. Br J Nutr. 2000;83(Supp 1):S143–8.PubMedGoogle Scholar
  86. 86.
    Andersen CJ, Fernandez ML. Dietary strategies to reduce metabolic syndrome. Rev Endocr Metab Disord. 2013 Aug 13. PMID23943309 [Epub ahead of print].Google Scholar
  87. 87.
    Lakka TA, Laaksonen DE. Physical activity in prevention and treatment of the metabolic syndrome. Appl Physiol Nutr Metab. 2007;3276–88.Google Scholar
  88. 88.
    Healy GN, Wijndaele K, Dunstan DW, et al. Objectively measured sedentary time, physical activity, and metabolic risk: the Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Diabetes Care. 2008;31:369–71.PubMedCrossRefGoogle Scholar
  89. 89.
    Ludwig DS. The glycemic index physiological mechanisms relating to obesity, diabetes, and cardiovascular disease. JAMA. 2002;287:2414–23.PubMedCrossRefGoogle Scholar
  90. 90.
    Babio N, Balanza R, Basulto J, Bulló M, Salas-Salvadó J. Dietary fibre: influence on body weight, glycemic control and plasma cholesterol profile. Nutr Hosp. 2010;25:327–40.PubMedGoogle Scholar
  91. 91.
    Aleixandre A, Miguel M. Dietary fiber in the prevention and treatment of metabolic syndrome: a review. Crit Rev Food Sci Nutr. 2008;48:905–12.PubMedCrossRefGoogle Scholar
  92. 92.
    Gillingham LG, Harris-Janz S, Jones PJ. Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids. 2011;46:209–28.PubMedCrossRefGoogle Scholar
  93. 93.
    Carpentier YA, Portois L, Malaisse WJ. Rapid enrichment of cell phospholipids in long-chain polyunsaturated ω-3 fatty acids after a bolus intravenous injection of a medium-chain triacylglycerol: fish oil emulsion in humans. J Parenter Enter Nutr. 2012;36:671–6.CrossRefGoogle Scholar
  94. 94.
    Chen J, Gu D, Huang J, Rao DC, et al. Metabolic syndrome and salt sensitivity of blood pressure in non-diabetic people in China: a dietary intervention study. Lancet. 2009;373:829–35.PubMedCrossRefGoogle Scholar
  95. 95.
    Shimamoto K, Hirata A, Fukuoka M, Higashiura K, Miyazaki Y, Shiiki M, et al. Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients. Hypertension. 1994;23:129–33.CrossRefGoogle Scholar
  96. 96.
    Galletti F, Strazzullo P, Ferrara I, Rivellese AA, Gatto S, Mancini M. Salt sensitivity of essential hypertensive patients is related to insulin resistance. J Hypertens. 1997;15:1485–91.PubMedCrossRefGoogle Scholar
  97. 97.
    Kaysen GA, Rathore V. Derangements of protein metabolism in chronic renal failure. Blood Purif. 1996;14(5):373–81.PubMedCrossRefGoogle Scholar
  98. 98.
    Slee AD. Exploring metabolic dysfunction in chronic kidney disease. Nutr Metab. 2012;9:36.CrossRefGoogle Scholar
  99. 99.
    Johnson RJ, Segal MS, Sautin Y, et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease. Am J Clin Nutr. 2007;86:899–906.PubMedGoogle Scholar
  100. 100.
    Giugliano D, Ceriello A, Esposito K. The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol. 2006;48:677–85.PubMedCrossRefGoogle Scholar
  101. 101.
    Kasajima H, Yamagishi S, Sugai S, Yagihashi N, Yagihashi S. Enhanced in situ expression of aldose reductase in peripheral nerve and renal glomeruli in diabetic patients. Virchows Arch. 2001;439:46–54.PubMedCrossRefGoogle Scholar
  102. 102.
    Tilton RG, Chang K, Pugliese G, Eades DM, Province MA, Sherman WR, et al. Prevention of hemodynamic and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes. 1989;38:1258–70.PubMedCrossRefGoogle Scholar
  103. 103.
    Robison Jr WG, Tillis TN, Laver N, Kinoshita JH. Diabetes-related histopathologies of the rat retina prevented with an aldose reductase inhibitor. Exp Eye Res. 1990;50:355–66.PubMedCrossRefGoogle Scholar
  104. 104.
    Kassab JP, Guillot R, Andre J, Claperon N, Bellon G, Feldmann G, et al. Renal and microvascular effects of an aldose reductase inhibitor in experimental diabetes. Biochemical, functional and ultrastructural studies. Biochem Pharmacol. 1994;48:1003–8.PubMedCrossRefGoogle Scholar
  105. 105.
    Reeves WB, Rawal BB, Abdel-Rahman EM, Awad AS. Therapeutic modalities in diabetic nephropathy: future approaches. Open J Nephrol. 2012;2:5–18.PubMedCrossRefGoogle Scholar
  106. 106.
    Saraswat M, Muthenna P, Suryanarayana P, Petrash JM, Reddy GB. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. Asia Pac J Clin Nutr. 2008;17:558–65.PubMedGoogle Scholar
  107. 107.
    Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med. 2002;8:337–46.PubMedGoogle Scholar
  108. 108.
    Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99:15596–601.PubMedCrossRefGoogle Scholar
  109. 109.
    Saraswat M, Reddy PY, Muthenna P, Reddy GB. Prevention of non-enzymic glycation of proteins by dietary agents: prospects for alleviating diabetic complications. Br J Nutr. 2009;101:1714–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • P. Anil Kumar
    • 1
    Email author
  • P. Swathi Chitra
    • 2
  • G. Bhanuprakash Reddy
    • 1
  1. 1.Department of BiochemistryNational Institute of NutritionHyderabadIndia
  2. 2.Department of BiochemistryThe Indira Gandhi National Open UniversityNew DelhiIndia

Personalised recommendations